Stonebridge Capital Advisors LLC raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,968 shares of the biopharmaceutical company’s stock after acquiring an additional 1,290 shares during the quarter. Stonebridge Capital Advisors LLC’s holdings in Pfizer were worth $1,474,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OLD Mission Capital LLC bought a new stake in shares of Pfizer in the third quarter valued at approximately $291,000. Morgan Stanley raised its position in shares of Pfizer by 3.4% in the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company’s stock valued at $1,875,532,000 after purchasing an additional 1,582,052 shares during the period. Center for Financial Planning Inc. raised its position in shares of Pfizer by 1.9% in the third quarter. Center for Financial Planning Inc. now owns 17,073 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 313 shares during the period. New World Advisors LLC bought a new stake in shares of Pfizer in the third quarter valued at approximately $292,000. Finally, EagleClaw Capital Managment LLC raised its position in shares of Pfizer by 2.1% in the third quarter. EagleClaw Capital Managment LLC now owns 29,959 shares of the biopharmaceutical company’s stock valued at $1,287,000 after purchasing an additional 625 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s stock.
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the sale, the senior vice president now directly owns 15,064 shares of the company’s stock, valued at approximately $760,732. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. During the same period last year, the company posted $0.93 EPS. Pfizer’s revenue for the quarter was up 76.8% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 6.6 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 annualized dividend and a yield of 2.97%. Pfizer’s payout ratio is currently 36.70%.
A number of research firms recently weighed in on PFE. Mizuho decreased their target price on shares of Pfizer from $56.00 to $55.00 in a report on Thursday, February 10th. SVB Leerink began coverage on shares of Pfizer in a report on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price on the stock. Wells Fargo & Company decreased their target price on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price on the stock. in a report on Tuesday, February 15th. Finally, Berenberg Bank set a $50.00 target price on shares of Pfizer in a report on Friday. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.00.
Pfizer Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.